New gene therapy success in a rare disease of the immune system: Wiskott-Aldrich syndrome
…
(read more)Effectiveness of innovative gene therapy treatment demonstrated in canine model of Duchenne muscular dystrophy
…
(read more)GENETHON and ESTEVE announce agreement to manufacture the gene therapy for the treatment of Sanfilippo Syndrome
…
(read more)Audentes Therapeutics and Genethon Announce Agreement to Develop Treatment for Severe Genetic Disease X‐Linked Myotubular Myopathy
…
(read more)Efficacy of gene therapy demonstrated in canine and murine models of myotubular myopathy
…
(read more)Généthon, the French AFM-Telethon laboratory, becomes the first not-for-profit to obtain authorization from ANSM to be a pharmaceutical manufacturer
…
(read more)The European charity Myotubular Trust is supporting Généthon in developing gene therapy for myotubular myopathy
…
(read more)Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial for an inherited immune deficiency: chronic granulomatous disease
…
(read more)Decree “advanced therapy medicinal products”: a new milestone for the AFM-Telethon and laboratory Genethon!
…
(read more)Genethon, member of the Biotherapies Institute for Rare Diseases
The Biotherapies Institute for Rare Diseases, a unique task force to accelerate therapeutic developments, includes 4 laboratories founded and supported by the AFM Telethon : the Institute of Myology, Genethon, I-Stem and Atlantic Gene Therapies (Nantes’ gene therapy research centre).
(read more)Alain Schwenck, an Expert on Pharmaceutical Prodcution, becomes Director of Genethon Bioprod
Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon.
(read more)Fulvio Mavilio, the internationally acknowledged expert in gene therapy for rare diseases, is appointed as Genethon’s new Scientific Director
…
(read more)Gene therapy : Encouraging results in a Phase I clinical trial in limb-girdle muscular dystrophy type 2C
…
(read more)